Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Does not change clinical practice; extends mechanistic insights into adipokine-mediated CVD and leaves open targeted intervention trials.
Epidemiological evidence has shown that abdominal obesity is closely associated with the development of cardiovascular (CV) disease, suggesting that it might be considered as an independent CV risk factor. However, the pathophysiological mechanisms responsible for the association between these 2 clinical entities remain largely unknown. Adipocytes are considered able to produce and secrete chemical mediators known as "adipokines" that may exert several biological actions, including those on heart and vessels. Of interest, a different adipokine profile can be observed in the plasma of patients with obesity or metabolic syndrome compared with healthy controls. We consider the main adipokines, focusing on their effects on the vascular wall and analyzing their role in CV pathophysiology.
No takes yet. Share an insight, caveat, or question.
Maresca et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: